106 related articles for article (PubMed ID: 38736259)
1. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
4. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
6. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: insights into mechanisms of lethality.
Rosato RR; Grant S
Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
[TBL] [Abstract][Full Text] [Related]
8. The role of histone deacetylases (HDACs) in human cancer.
Ropero S; Esteller M
Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
[TBL] [Abstract][Full Text] [Related]
9. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
11. HDAC Inhibitors.
Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
[TBL] [Abstract][Full Text] [Related]
12. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
13. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
14. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: a patent review (2009 - 2011).
Carafa V; Miceli M; Altucci L; Nebbioso A
Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
Cui Y; Cai J; Wang W; Wang S
Front Immunol; 2021; 12():690207. PubMed ID: 34149732
[TBL] [Abstract][Full Text] [Related]
17. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
[TBL] [Abstract][Full Text] [Related]
18. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Koutsounas I; Giaginis C; Patsouris E; Theocharis S
World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
[TBL] [Abstract][Full Text] [Related]
19. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
20. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
